# Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

> **NCT05369052** · PHASE3 · RECRUITING · sponsor: **MicuRx** · enrollment: 865 (estimated)

## Conditions studied

- Diabetic Foot Infection

## Interventions

- **DRUG:** contezolid acefosamil (IV)/contezolid (PO)
- **DRUG:** Linezolid (IV and PO)

## Key facts

- **NCT ID:** NCT05369052
- **Lead sponsor:** MicuRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 865 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05369052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05369052, "Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05369052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*